Parameters | Outcomes | Incremental costs | ICER | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
 | DALY averted | QALY gained |  |  |  |  | Per DALY averted | Per QALY gained | ||||
 | TriVac (default) | TriVac (± 20%) | ADIP (± 20%) | SUPR (± 20%) | TriVac (default) | TriVac (± 20%) | ADIP (± 20%) | SUPR (± 20%) | TriVac (default) | TriVac (± 20%) | ADIP (± 20%) | SUPR (± 20%) |
Population: | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Total number of births per year | + | + | ++ | 0 | + | + | +++ | ++++ | + | + | Â | ++ |
Life expectancy at birth | 0 | + | ++ | ++ | 0 | 0 | + | 0 | 0 | + | Â | ++ |
Under 5 years mortality per 1,000 live births | 0 | ++ | - | - | 0 | + | - | - | 0 | ++ | Â | - |
Burden of disease: | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Incidence of pneumococcal pneumonia (per 100,000 per year) | ++ | ++ | ++ | - | + | + | ++++ | - | ++ | ++ | Â | - |
Incidence of meningitis (per 100,000 per year) | ++ | + | + | - | + | + | + | - | ++ | + | Â | - |
Incidence of invasive NPNM (per 100,000 per year) | ++ | ++ | + | - | + | + | + | - | ++ | ++ | Â | - |
Prevalence of bacteremia sp < 10 years (cases per year) | - | - | - | ++ | - | - | - | + | - | - | Â | ++ |
Case fatality rate of pneumococcal pneumonia | 0 | ++ | ++ | + | 0 | 0 | + | 0 | 0 | ++ | Â | + |
Case fatality rate of invasive NPNM | 0 | ++ | + | ++ | 0 | 0 | + | 0 | 0 | ++ | Â | ++ |
Vaccine information: | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Vaccine efficacy of pneumococcal pneumonia | ++ | ++ | ++ | ++ | + | + | + | + | ++ | ++ | Â | ++ |
Vaccine efficacy of pneumococcal invasive NPNM | + | ++ | + | ++ | + | + | + | + | + | ++ | Â | ++ |
Vaccine efficacy adjusted NTHi | - | - | - | ++ | - | - | - | + | - | - | Â | ++ |
Vaccine coverage | + | + | ++ | ++ | + | ++ | ++++ | +++ | + | + | Â | ++ |
Serotype coverage of pneumococcal pneumonia | +++ | ++ | ++ | + | + | + | ++++ | + | +++ | ++ | Â | ++ |
Number of doses | - | - | - | + | - | - | - | +++ | - | - | Â | +++ |
Dose cost | 0 | 0 | 0 | 0 | 0 | +++ | ++ | +++ | 0 | ++ | Â | ++ |
Other parameters: | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Coverage 20 years after vaccine introduced (dose 1) | + | ++ | - | - | + | ++ | - | - | + | ++ | Â | - |
Coverage 20 years after vaccine introduced (dose 3) | + | ++ | - | - | + | ++ | - | - | + | ++ | Â | - |
GP visits < 10 years (AOM) | - | - | - | ++ | - | - | - | + | - | - | Â | ++ |
Proportion sp of AOM | Â | Â | Â | Â | Â | Â | - | Â | - | - | Â | ++ |
Probability of death | - | - | - | ++ | - | - | - | 0 | - | - | Â | ++ |